Creo Medical is a medical device company focused on the emerging field of surgical endoscopy, a recent development in minimally invasive surgery. The company’s mission is to improve patient outcomes by applying microwave and radiofrequency energy to surgical endoscopy.
Creo has developed CROMA, an electrosurgical platform that can deliver bipolar radiofrequency energy and microwave power through a single accessory port. This technology makes it possible to perform endoscopic surgery with precision through miniature endoscopic instruments that cut, coagulate and ablate soft tissue. Creo Medical’s strategy is to further develop the CROMA platform through a suite of new medical, initially into the field of gastrointestinal (GI) tract therapeutic endoscopy, and then into a broader range of areas including bronchoscopy and laparoscopy.
MaxCyte is a U.S.-based global company driving the acceleration of the discovery/ development, manufacturing and commercialization of next-generation, cell-based medicines.
The group provides its patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, its team of scientific experts helps the group’s partners unlock the potential of their products and solve development and commercialization challenges.
RenalytixAI is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs.
KidneyIntelX, the group’s first-in-class in vitro diagnostics platform, employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
Synairgen is a drug discovery and development company founded by three Professors at the University of Southampton. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease.
In July this year, Synairgen announced positive results from its Phase II double-blind placebo-controlled trial, called SG016, in hospitalised COVID-19 patients. The primary endpoint was the change in condition assessed using the WHO Ordinal Scale for Clinical Improvement (OSCI) during the dosing period.